top
Please input keywords
Order
*Country
日本
アメリカ
中国
オーストラリア
シンガポール
イギリス
フランス
ドイツ
スイス
イタリア
カナダ
韓国
オランダ
ベルギー
スウェーデン
その他
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hCCN2 mice
Strain Name
C57BL/6N-Ccn2tm2(CCN2)Bcgen/Bcgen
Common Name  B-hCCN2 mice
Background  C57BL/6N Catalog number 111523
Related Genes  CCN2,cellular communication network factor 2,CTGF, HCS24, IGFBP8, NOV2

mRNA expression analysis

from clipboard


Strain specific analysis of CCN2 gene expression in wild-type mice and B-hCCN2 mice by RT-PCR. Mouse Ccn2 mRNA was detectable in kidney of wild-type mice (+/+). Human CCN2 mRNA was detectable only in homozygous B-hCCN1 mice but not in wild-type mice.

from clipboard


Strain specific CCN2 expression analysis in homozygous B-hCCN2 mice by Western blot. Kidney tissue was collected from wild-type C57BL/6 mice (+/+) and homozygous B-hCCN2 mice (H/H), and analyzed by western blot with anti-CCN2 antibody. CCN2 was detectable in wild type mice and homozygous B-hCCN2 mice, as the antibody is crossly reactive with CCN2 in human and mice.

In vivo efficacy of anti-human CCN2 antibody with bleomycin-induced B-hCCN2 mice


from clipboard


Anti-human CCN2 antibody inhibits collagen deposition in lungs of bleomycin-treated  B-hCCN2 mice. B-hCCN2 mice were assigned to one saline non-bleomycin control group (n=4) and two bleomycin-treated fibrosis groups (n=9) which were treated with pamrevlumab (in house, anti-human CCN2) or vehicle. Pamrevlumab treatment was able to improve bleomycin-induced weight loss in B-hCCN2 mice(A). Fibrosis in this model was scored by the standard measure of total lung HYP. In control mice, bleomycin treatment increases HYP content compared with controls. Compared with vehicle-treated bleomycin controls, pamrevlumab treatment resulted in a reduction in mean induced lung HYP content (B).  Values are expressed as mean ± SEM. *** p<0.001, **p<0.01.